UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 62 filers reported holding UROGEN PHARMA LTD in Q3 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120 | +37.9% | 8,600 | +2.4% | 0.00% | – |
| Q2 2023 | $87 | -91.3% | 8,400 | +4727.6% | 0.00% | – |
| Q2 2022 | $1,000 | -99.2% | 174 | -98.7% | 0.00% | – |
| Q1 2022 | $118,000 | -8.5% | 13,574 | -0.1% | 0.00% | – |
| Q4 2021 | $129,000 | -50.6% | 13,592 | -12.3% | 0.00% | – |
| Q3 2021 | $261,000 | -8.4% | 15,501 | -16.9% | 0.00% | – |
| Q2 2021 | $285,000 | -22.6% | 18,658 | -1.3% | 0.00% | – |
| Q1 2021 | $368,000 | +2.5% | 18,900 | -5.0% | 0.00% | – |
| Q4 2020 | $359,000 | -6.5% | 19,900 | 0.0% | 0.00% | – |
| Q3 2020 | $384,000 | -26.2% | 19,900 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $520,000 | +78.7% | 19,900 | +22.1% | 0.00% | – |
| Q1 2020 | $291,000 | -46.5% | 16,300 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $544,000 | +18.8% | 16,300 | -15.1% | 0.00% | 0.0% |
| Q3 2019 | $458,000 | -33.6% | 19,200 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $690,000 | – | 19,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |